CLDX Overview
Upcoming Projects (CLDX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CLDX)
-
Discussing the 52 week results of the Barzolvolimab Phase 2 study in CSU (Chronic Spontaneous Urticaria) at EADV 2024
Tickers: CLDX, JSPR, REGN, NVS
Executed On: Oct 09, 2024 at 12:00 PM EDT -
A second look: Discussing the recent phase 2 data of barzolvolimab in two of the most common forms of CIndU - Cold Urticaria and symptomatic dermographism
Ticker: CLDX
Executed On: Aug 06, 2024 at 01:30 PM EDT -
Discussing the recent phase 2 data of barzolvolimab in two of the most common forms of CIndU - Cold Urticaria and symptomatic dermographism
Ticker: CLDX
Executed On: Aug 01, 2024 at 10:00 AM EDT -
Evaluating the Breakthrough in Chronic Spontaneous Urticaria Treatment: A Deep Dive into Celldex Therapeutics' Barzolvolimab CDX-0159 Phase 2 Study
Ticker: CLDX
Executed On: Mar 21, 2024 at 12:00 PM EDT -
Evaluating Celldex Therapeutics' Barzolvolimab (CDX-0159) for the Treatment of Chronic Spontaneous Urticaria (CSU)
Ticker: CLDX
Executed On: Nov 30, 2023 at 10:00 AM EST -
Discussing C-Kit targeting for CSU (chronic spontaneous urticaria), PN (prurigo nodularis, EOE (eosinophilic esophagitis), aSM (advanced systemic mastocytosis), and iSM (indolent systemic mastocytosis)
Tickers: CLDX, JSPR, BPMC, COGT
Executed On: Sep 12, 2023 at 10:30 AM EDT -
A Second View: Discussing the updated Phase 1B data for Celldex' barzolvolimab in chronic spontaneous urticaria (CSU) with a community immunologist
Ticker: CLDX
Executed On: Mar 17, 2023 at 11:00 AM EDT -
Discussing the updated Phase 1B data for Celldex' barzolvolimab in chronic spontaneous urticaria (CSU) with an allergist
Ticker: CLDX
Executed On: Mar 10, 2023 at 09:00 AM EST -
A Second View: Discussing the recent Phase 1B data from Celldex on Barzolvolimab (CDX-0159) in treating Spontaneous Urticaria
Ticker: CLDX
Executed On: Jul 22, 2022 at 10:00 AM EDT -
Discussing the recent Phase 1B data from Celldex on Barzolvolimab (CDX-0159) in treating Spontaneous Urticaria
Ticker: CLDX
Executed On: Jul 20, 2022 at 11:30 AM EDT -
Discussing Celldex' CDX-0159 Urticaria Phase 1b Data presented at EAACI 2021
Ticker: CLDX
Executed On: Feb 10, 2022 at 11:30 AM EST -
A Conversation on the Chronic Urticaria Landscape
Tickers: CLDX, NVS, RHHBF
Executed On: Jan 04, 2022 at 12:00 PM EST
Upcoming & Overdue Catalysts (CLDX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CLDX)
-
Celldex Therapeutics (CLDX) Presents Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
Ticker: CLDX
Occurred on: Jul 09, 2021 -
Celldex (CLDX) Reports Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria
Ticker: CLDX
Occurred on: Mar 29, 2021 -
Celldex (CLDX) Presents Phase 2 Data Evaluating Glembatumumab Vedotin in Metastatic Melanoma
Ticker: CLDX
Occurred on: Oct 09, 2016 -
New Clinical and Preclinical Data to be Presented at AACR Annual Meeting
Ticker: CLDX
Occurred on: Apr 20, 2016 -
Development of Varlilumab and Nivolumab (Opdivo) to Advance to Phase 2 Study - Open Enrollment to Begin Q2 of 2016
Tickers: CLDX, BMY
Occurred on: Apr 18, 2016 -
RINTEGA Product Profile Set to Expand - Celldex set to Initiate Additional Studies in Glioblastoma and Combination Treatments
Ticker: CLDX
Occurred on: Mar 07, 2016 -
Phase 3 second interim analysis of CDX-110 rindopepimut - ACT IV for glioblastoma multiforme (GBM) front line due early 2016
Ticker: CLDX
Occurred on: Mar 07, 2016 -
Celldex Presents Preliminary Cohort Data from Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Harvest
Ticker: CLDX
Occurred on: Feb 20, 2016
Strategic Initiatives (CLDX)
-
Celldex (CLDX) Agrees to Acquire Privately Held Koltan Pharmaceuticals in All-Stock Deal for up to $235MM
Tickers: CLDX, Koltan Pharmaceuticals
Announcement Date: Nov 02, 2016
